Clinilabs, a contract research organization (CRO) specializing in early phase and specialty studies, has entered into a collaborative agreement with the Epilepsy Study Consortium. This agreement allows Clinilabs and the Epilepsy Study Consortium to provide integrated consultation and clinical drug development services to pharmaceutical and biotechnology companies conducting phase-I and II trials of antiepileptic drugs (AEDs).

The Epilepsy Study Consortium is a group of scientific investigators from academic medical research centers dedicated to accelerating the development of new therapies in epilepsy to improve patient care. The organization's goals include building a partnership between academics, industry, and regulatory agencies, and optimizing clinical trial methodology in order to responsibly speed new treatments to patients.

Dr Gary K Zammit, president & CEO of Clinilabs Inc, said, "We believe that this collaboration offers a seamless approach to the development of AEDs, providing drug companies with the scientific and operational expertise they need to bring new and better medicines to the market."

With this agreement, Dr Jacqueline French, president of the Epilepsy Study Consortium, will be appointed to Clinilabs' Scientific Advisory Board. She will join advisors Dr David Greenblatt (Tufts University School of Medicine), Dr Paul Schweitzer (New York University Medical Center), and Daniel Goodman.

"We are pleased to enter into this collaboration, which we hope will lead to more productive, innovative and efficient trials of AEDs," stated Dr Jacqueline French, President of the Epilepsy Study Consortium.

Clinilabs is CRO that provides early phase and specialty clinical drug development services to industry.

The Epilepsy Study Consortium is a group of scientific investigators from academic medical research centers who are dedicated to accelerating the development of new therapies in epilepsy to improve patient care.